Figure S2 from Trends in Gastric Cancer Incidence, Mortality, and Survival by Histologic Subtype in the United States (2000–2022) and a Contemporary Chinese Cohort

Authors: Kailai Yin, Shanshan Wang, Yanan Wang et al.

Publication:

Published: Unknown date

Source: Crossref

Back to Search View Original Cite This Article

Abstract

<jats:p><p>Distribution of SEER summary stage across histologic subtypes by time period in the SEER cohort. Stacked horizontal bars show the proportions of localized, regional, and distant stage disease for each histologic subtype in the SEER cohort across three time periods: 2000–2005, 2006–2011, and 2012–2017. Percentages are displayed within the bars. GAC, gastric adenocarcinoma; G-NET, gastric neuroendocrine tumor; G-NEC/MiNEN, gastric neuroendocrine carcinoma/mixed neuroendocrine-non-neuroendocrine neoplasm; GCSC, gastric carcinoma with squamous component; UGC, undifferentiated gastric carcinoma.</p></jats:p>

Keywords

gastric seer stage histologic time

Figure S2 from Trends in Gastric Cancer Incidence, Mortality, and Survival by Histologic Subtype in the United States (2000–2022) and a Contemporary Chinese Cohort

Abstract

Keywords

Related Articles

Supplementary Figure S3 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade

Supplementary Table S2 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies

Supplementary Table S6 from &lt;i&gt;Helicobacter pylori&lt;/i&gt; Infection and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis

Data from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies

Supplemental Table S4 from Performance of Statistical and Machine Learning Risk Prediction Models for Advanced Breast Cancer

Supplementary Table S6 from <i>Helicobacter pylori</i> Infection and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis